A novel pharmaceutical composition comprising the NK.sub.3 receptor antagonist talnetant, povidone, erythritol and a surfactant, and a process for its preparation are disclosed. The use of erythritol as soluble filler in the preparation of a stable pharmaceutical composition is disclosed.

 
Web www.patentalert.com

< Compounds for Treating Protein-Kinase Mediated Disorders

> 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof

~ 00475